Combining anti-PD-1 antibodies with surufatinib for gastrointestinal neuroendocrine carcinoma: Two cases report and review of literature

Figure 2 Imaging and laboratory tests of these cases and the course of TACE treatment of the patient in case 2. A: Colonoscopy revealed scar-like changes in the original rectal lesion with distorted surrounding mucosa; B: Microscopy of the biopsy sample revealed chronic inflammation with lymphocyte infiltration; C: PET/CT revealed no hypermetabolic uptake in the rectum or left neck, with several residual lymph nodes in the abdomen. Computed tomography (CT) at diagnosis revealed irregular thickening of the rectal wall with uneven enhancement and multiple enlarged nodes in the pelvic cavity, abdomen, and left neck; D: CT images at 1 month after surgery, 4 cycles (PD) of etoposide + carboplatin, 3 cycles (PD) of irinotecan + raltitrexed, and 3 cycles (PD) of xelox + bevacizumab. Sintilimab + surufatinib (ICI-TKI) continuous treatment (TACE of hepatic metastasis 2021-04-27); E: Dynamics of NSE during the treatment process.